SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-097522
Filing Date
2021-03-29
Accepted
2021-03-29 08:35:59
Documents
7
Period of Report
2021-03-29
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d147326d8k.htm 8-K 32261
2 EX-3.1 d147326dex31.htm EX-3.1 12628
3 EX-3.2 d147326dex32.htm EX-3.2 207198
4 EX-99.1 d147326dex991.htm EX-99.1 10654
5 GRAPHIC g147326g0327232352915.jpg GRAPHIC 5339
6 GRAPHIC g147326sumi_logo.jpg GRAPHIC 6820
7 GRAPHIC g147326urovant_logo.jpg GRAPHIC 4948
  Complete submission text file 0001193125-21-097522.txt   288396
Mailing Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617
Business Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617 949-226-6029
Urovant Sciences Ltd. (Filer) CIK: 0001740547 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38667 | Film No.: 21779616
SIC: 2834 Pharmaceutical Preparations